US 10946106
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
granted A61KA61K2039/505A61K2039/572
Quick answer
US patent 10946106 (Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen) held by The Regents of the University of California expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K2039/572, A61K35/00, A61K35/17